Faster And Cheaper: Similis Bio Aims To Enhance Biosimilar Development
Intends Deal With Blau Farmaceutica To Be ‘First Of Many’ Parallel Partnerships
In the wake of Similis Bio’s first biosimilar partnership, the JSR Life Sciences unit’s head, John Gabrielson, talks to Generics Bulletin about the Similis Bio model and how the firm believes it can help bring biosimilars to market more rapidly and efficiently.
